Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
55
ANIP Quote, Financials, Valuation and Earnings
Last price:
$82.11
Seasonality move
:
9.58%
Day range:
$80.42 - $82.36
52-week range:
$52.74 - $99.50
Dividend yield:
0%
P/E ratio:
50.36x
P/S ratio:
2.01x
P/B ratio:
3.65x
Volume:
516.5K
Avg. volume:
445.3K
1-year change:
51.74%
Market cap:
$1.8B
Revenue:
$614.4M
EPS (TTM):
$1.63
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ANIP
ANI Pharmaceuticals, Inc.
|
$212.9M | $1.77 | 21.97% | 68.6% | $109.25 |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$87M | -$0.09 | 53.91% | -88.43% | $31.63 |
|
CRMD
CorMedix, Inc.
|
$86M | $0.63 | 308.6% | 219.78% | $19.00 |
|
CSTL
Castle Biosciences, Inc.
|
$71.1M | -$0.51 | -11.48% | -26.99% | $40.38 |
|
FOLD
Amicus Therapeutics, Inc.
|
$165.7M | $0.12 | 20.08% | 236.17% | $15.25 |
|
NTLA
Intellia Therapeutics, Inc.
|
$14.1M | -$1.00 | -5.94% | -24.06% | $22.43 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ANIP
ANI Pharmaceuticals, Inc.
|
$82.11 | $109.25 | $1.8B | 50.36x | $0.00 | 0% | 2.01x |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$29.44 | $31.63 | $3.6B | -- | $0.00 | 0% | 11.83x |
|
CRMD
CorMedix, Inc.
|
$12.19 | $19.00 | $960.4M | 5.94x | $0.00 | 0% | 4.10x |
|
CSTL
Castle Biosciences, Inc.
|
$40.09 | $40.38 | $1.2B | 30.24x | $0.00 | 0% | 3.43x |
|
FOLD
Amicus Therapeutics, Inc.
|
$14.25 | $15.25 | $4.4B | -- | $0.00 | 0% | 7.29x |
|
NTLA
Intellia Therapeutics, Inc.
|
$9.59 | $22.43 | $1.1B | -- | $0.00 | 0% | 17.47x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ANIP
ANI Pharmaceuticals, Inc.
|
55.53% | -0.550 | 30.7% | 2.40x |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
41.85% | -0.694 | 5.02% | 3.07x |
|
CRMD
CorMedix, Inc.
|
1.16% | 3.481 | 0.48% | 1.60x |
|
CSTL
Castle Biosciences, Inc.
|
7.37% | 1.094 | 5.59% | 6.09x |
|
FOLD
Amicus Therapeutics, Inc.
|
65.77% | 0.379 | 18.22% | 1.91x |
|
NTLA
Intellia Therapeutics, Inc.
|
11.58% | 3.323 | 4.9% | 5.57x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ANIP
ANI Pharmaceuticals, Inc.
|
$111.8M | $22.8M | 3.31% | 8.22% | 10.02% | $37.9M |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$90.5M | $8.5M | -15.75% | -29.4% | 8.59% | -$1.8M |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
CSTL
Castle Biosciences, Inc.
|
$61.5M | -$6.8M | -2.54% | -2.71% | -8.19% | $7.8M |
|
FOLD
Amicus Therapeutics, Inc.
|
$147.7M | $34.3M | -2.18% | -7.02% | 20.27% | $35.3M |
|
NTLA
Intellia Therapeutics, Inc.
|
$8.8M | -$111.5M | -47.33% | -54.66% | -808.86% | -$76.9M |
ANI Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns ANIP or ARQT?
Arcutis Biotherapeutics, Inc. has a net margin of 10.59% compared to ANI Pharmaceuticals, Inc.'s net margin of 7.47%. ANI Pharmaceuticals, Inc.'s return on equity of 8.22% beat Arcutis Biotherapeutics, Inc.'s return on equity of -29.4%.
Company Gross Margin Earnings Per Share Invested Capital ANIPANI Pharmaceuticals, Inc.49.07% $1.13 $1.1B ARQTArcutis Biotherapeutics, Inc.91.25% $0.06 $271.8M -
What do Analysts Say About ANIP or ARQT?
ANI Pharmaceuticals, Inc. has a consensus price target of $109.25, signalling upside risk potential of 35.33%. On the other hand Arcutis Biotherapeutics, Inc. has an analysts' consensus of $31.63 which suggests that it could grow by 7.9%. Given that ANI Pharmaceuticals, Inc. has higher upside potential than Arcutis Biotherapeutics, Inc., analysts believe ANI Pharmaceuticals, Inc. is more attractive than Arcutis Biotherapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ANIPANI Pharmaceuticals, Inc.4 1 0 ARQTArcutis Biotherapeutics, Inc.5 1 0 -
Is ANIP or ARQT More Risky?
ANI Pharmaceuticals, Inc. has a beta of 0.484, which suggesting that the stock is 51.639% less volatile than S&P 500. In comparison Arcutis Biotherapeutics, Inc. has a beta of 1.693, suggesting its more volatile than the S&P 500 by 69.345%.
-
Which is a Better Dividend Stock ANIP or ARQT?
ANI Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arcutis Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ANI Pharmaceuticals, Inc. pays 8.77% of its earnings as a dividend. Arcutis Biotherapeutics, Inc. pays out -- of its earnings as a dividend. ANI Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ANIP or ARQT?
ANI Pharmaceuticals, Inc. quarterly revenues are $227.8M, which are larger than Arcutis Biotherapeutics, Inc. quarterly revenues of $99.2M. ANI Pharmaceuticals, Inc.'s net income of $24.1M is higher than Arcutis Biotherapeutics, Inc.'s net income of $7.4M. Notably, ANI Pharmaceuticals, Inc.'s price-to-earnings ratio is 50.36x while Arcutis Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ANI Pharmaceuticals, Inc. is 2.01x versus 11.83x for Arcutis Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ANIPANI Pharmaceuticals, Inc.2.01x 50.36x $227.8M $24.1M ARQTArcutis Biotherapeutics, Inc.11.83x -- $99.2M $7.4M
-
Which has Higher Returns ANIP or CRMD?
CorMedix, Inc. has a net margin of 10.59% compared to ANI Pharmaceuticals, Inc.'s net margin of 49.9%. ANI Pharmaceuticals, Inc.'s return on equity of 8.22% beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital ANIPANI Pharmaceuticals, Inc.49.07% $1.13 $1.1B CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About ANIP or CRMD?
ANI Pharmaceuticals, Inc. has a consensus price target of $109.25, signalling upside risk potential of 35.33%. On the other hand CorMedix, Inc. has an analysts' consensus of $19.00 which suggests that it could grow by 55.87%. Given that CorMedix, Inc. has higher upside potential than ANI Pharmaceuticals, Inc., analysts believe CorMedix, Inc. is more attractive than ANI Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ANIPANI Pharmaceuticals, Inc.4 1 0 CRMDCorMedix, Inc.4 0 0 -
Is ANIP or CRMD More Risky?
ANI Pharmaceuticals, Inc. has a beta of 0.484, which suggesting that the stock is 51.639% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.322, suggesting its more volatile than the S&P 500 by 32.155%.
-
Which is a Better Dividend Stock ANIP or CRMD?
ANI Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ANI Pharmaceuticals, Inc. pays 8.77% of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend. ANI Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ANIP or CRMD?
ANI Pharmaceuticals, Inc. quarterly revenues are $227.8M, which are larger than CorMedix, Inc. quarterly revenues of $104.3M. ANI Pharmaceuticals, Inc.'s net income of $24.1M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, ANI Pharmaceuticals, Inc.'s price-to-earnings ratio is 50.36x while CorMedix, Inc.'s PE ratio is 5.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ANI Pharmaceuticals, Inc. is 2.01x versus 4.10x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ANIPANI Pharmaceuticals, Inc.2.01x 50.36x $227.8M $24.1M CRMDCorMedix, Inc.4.10x 5.94x $104.3M $108.6M
-
Which has Higher Returns ANIP or CSTL?
Castle Biosciences, Inc. has a net margin of 10.59% compared to ANI Pharmaceuticals, Inc.'s net margin of -0.6%. ANI Pharmaceuticals, Inc.'s return on equity of 8.22% beat Castle Biosciences, Inc.'s return on equity of -2.71%.
Company Gross Margin Earnings Per Share Invested Capital ANIPANI Pharmaceuticals, Inc.49.07% $1.13 $1.1B CSTLCastle Biosciences, Inc.74.09% -$0.02 $504.2M -
What do Analysts Say About ANIP or CSTL?
ANI Pharmaceuticals, Inc. has a consensus price target of $109.25, signalling upside risk potential of 35.33%. On the other hand Castle Biosciences, Inc. has an analysts' consensus of $40.38 which suggests that it could grow by 0.71%. Given that ANI Pharmaceuticals, Inc. has higher upside potential than Castle Biosciences, Inc., analysts believe ANI Pharmaceuticals, Inc. is more attractive than Castle Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ANIPANI Pharmaceuticals, Inc.4 1 0 CSTLCastle Biosciences, Inc.8 0 0 -
Is ANIP or CSTL More Risky?
ANI Pharmaceuticals, Inc. has a beta of 0.484, which suggesting that the stock is 51.639% less volatile than S&P 500. In comparison Castle Biosciences, Inc. has a beta of 1.142, suggesting its more volatile than the S&P 500 by 14.213%.
-
Which is a Better Dividend Stock ANIP or CSTL?
ANI Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Castle Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ANI Pharmaceuticals, Inc. pays 8.77% of its earnings as a dividend. Castle Biosciences, Inc. pays out -- of its earnings as a dividend. ANI Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ANIP or CSTL?
ANI Pharmaceuticals, Inc. quarterly revenues are $227.8M, which are larger than Castle Biosciences, Inc. quarterly revenues of $83M. ANI Pharmaceuticals, Inc.'s net income of $24.1M is higher than Castle Biosciences, Inc.'s net income of -$501K. Notably, ANI Pharmaceuticals, Inc.'s price-to-earnings ratio is 50.36x while Castle Biosciences, Inc.'s PE ratio is 30.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ANI Pharmaceuticals, Inc. is 2.01x versus 3.43x for Castle Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ANIPANI Pharmaceuticals, Inc.2.01x 50.36x $227.8M $24.1M CSTLCastle Biosciences, Inc.3.43x 30.24x $83M -$501K
-
Which has Higher Returns ANIP or FOLD?
Amicus Therapeutics, Inc. has a net margin of 10.59% compared to ANI Pharmaceuticals, Inc.'s net margin of 10.24%. ANI Pharmaceuticals, Inc.'s return on equity of 8.22% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.
Company Gross Margin Earnings Per Share Invested Capital ANIPANI Pharmaceuticals, Inc.49.07% $1.13 $1.1B FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M -
What do Analysts Say About ANIP or FOLD?
ANI Pharmaceuticals, Inc. has a consensus price target of $109.25, signalling upside risk potential of 35.33%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $15.25 which suggests that it could grow by 7.02%. Given that ANI Pharmaceuticals, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe ANI Pharmaceuticals, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ANIPANI Pharmaceuticals, Inc.4 1 0 FOLDAmicus Therapeutics, Inc.3 4 0 -
Is ANIP or FOLD More Risky?
ANI Pharmaceuticals, Inc. has a beta of 0.484, which suggesting that the stock is 51.639% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.463, suggesting its less volatile than the S&P 500 by 53.675%.
-
Which is a Better Dividend Stock ANIP or FOLD?
ANI Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ANI Pharmaceuticals, Inc. pays 8.77% of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend. ANI Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ANIP or FOLD?
ANI Pharmaceuticals, Inc. quarterly revenues are $227.8M, which are larger than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. ANI Pharmaceuticals, Inc.'s net income of $24.1M is higher than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, ANI Pharmaceuticals, Inc.'s price-to-earnings ratio is 50.36x while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ANI Pharmaceuticals, Inc. is 2.01x versus 7.29x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ANIPANI Pharmaceuticals, Inc.2.01x 50.36x $227.8M $24.1M FOLDAmicus Therapeutics, Inc.7.29x -- $169.1M $17.3M
-
Which has Higher Returns ANIP or NTLA?
Intellia Therapeutics, Inc. has a net margin of 10.59% compared to ANI Pharmaceuticals, Inc.'s net margin of -735.19%. ANI Pharmaceuticals, Inc.'s return on equity of 8.22% beat Intellia Therapeutics, Inc.'s return on equity of -54.66%.
Company Gross Margin Earnings Per Share Invested Capital ANIPANI Pharmaceuticals, Inc.49.07% $1.13 $1.1B NTLAIntellia Therapeutics, Inc.64.19% -$0.92 $846.4M -
What do Analysts Say About ANIP or NTLA?
ANI Pharmaceuticals, Inc. has a consensus price target of $109.25, signalling upside risk potential of 35.33%. On the other hand Intellia Therapeutics, Inc. has an analysts' consensus of $22.43 which suggests that it could grow by 133.91%. Given that Intellia Therapeutics, Inc. has higher upside potential than ANI Pharmaceuticals, Inc., analysts believe Intellia Therapeutics, Inc. is more attractive than ANI Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ANIPANI Pharmaceuticals, Inc.4 1 0 NTLAIntellia Therapeutics, Inc.10 11 1 -
Is ANIP or NTLA More Risky?
ANI Pharmaceuticals, Inc. has a beta of 0.484, which suggesting that the stock is 51.639% less volatile than S&P 500. In comparison Intellia Therapeutics, Inc. has a beta of 2.133, suggesting its more volatile than the S&P 500 by 113.344%.
-
Which is a Better Dividend Stock ANIP or NTLA?
ANI Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intellia Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ANI Pharmaceuticals, Inc. pays 8.77% of its earnings as a dividend. Intellia Therapeutics, Inc. pays out -- of its earnings as a dividend. ANI Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ANIP or NTLA?
ANI Pharmaceuticals, Inc. quarterly revenues are $227.8M, which are larger than Intellia Therapeutics, Inc. quarterly revenues of $13.8M. ANI Pharmaceuticals, Inc.'s net income of $24.1M is higher than Intellia Therapeutics, Inc.'s net income of -$101.3M. Notably, ANI Pharmaceuticals, Inc.'s price-to-earnings ratio is 50.36x while Intellia Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ANI Pharmaceuticals, Inc. is 2.01x versus 17.47x for Intellia Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ANIPANI Pharmaceuticals, Inc.2.01x 50.36x $227.8M $24.1M NTLAIntellia Therapeutics, Inc.17.47x -- $13.8M -$101.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
56
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
